{"id":"W4241454646","doi":"10.3747/co.v18is2.958","title":"Progression-Free Survival as a Clinical Trial Endpoint in Advanced Renal Cell Carcinoma","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; University of Toronto; Western University; Centre Hospitalier de l’Université de Montréal; University Health Network; Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa; BC Cancer Agency; Princess Margaret Cancer Centre; St. Michael's Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Clinical trial; Renal cell carcinoma; Intensive care medicine; Progression-free survival; Oncology; Endpoint Determination; Overall survival; Disease; Surrogate endpoint; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.02242111,0.0002540187,0.001602326,0.0003673204,0.00009880457,0.00002105258,0.0006053629,0.000356051,0.001255864],"category_scores_gemma":[0.006906473,0.0002991371,0.0002503376,0.0002041471,0.0001749198,0.0002698574,0.0002403674,0.0006332436,0.002176566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007220104,"about_ca_system_score_gemma":0.0006621698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002443278,"about_ca_topic_score_gemma":0.0004066125,"domain_scores_codex":[0.9908206,0.001326573,0.006168646,0.0009057338,0.0001293405,0.0006490432],"domain_scores_gemma":[0.9944714,0.001598355,0.002675012,0.0008507374,0.00007046682,0.0003340408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02256135,0.009910317,0.735221,0.0006382428,0.00007819267,0.00006585279,0.009234918,0.00001243269,0.000003503222,0.1289128,0.04720075,0.04616061],"study_design_scores_gemma":[0.1048923,0.005808631,0.3190557,0.0001229097,0.0000225089,0.00001030831,0.001504859,0.0008420387,0.00003001848,0.06586181,0.5008583,0.0009905526],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9513058,0.002909648,0.0004558603,0.003713225,0.01023018,0.001767369,0.0001288219,0.00005684923,0.02943221],"genre_scores_gemma":[0.9907379,0.0002766592,0.004953547,0.001391742,0.001633144,0.0006248219,0.0000718443,0.00005085549,0.000259525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4536575,"threshold_uncertainty_score":0.9999461,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.7607084304829609,"score_gpt":0.579968775289633,"score_spread":0.1807396551933279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}